|
2017 Journal Article Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic MelanomaBossart, Simon, Thurneysen, Selina, Rushing, Elisabeth, Frontzek, Karl, Leske, Henning, Mihic-Probst, Daniela, Nagel, Hannes W., Mangana, Johanna, Goldinger, Simone M. and Dummer, Reinhard (2017). Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma. Oncologist, 22 (6), 749-753. doi: 10.1634/theoncologist.2016-0366 |
|
2017 Conference Publication Sarcoid-like reactions under modern melanoma treatmentDimitriou, F., Frauchiger, A., Goldinger, S. M., Braun, R., Mangana, J. and Dummer, R. (2017). Sarcoid-like reactions under modern melanoma treatment. HOBOKEN: WILEY. |
|
2017 Conference Publication Thin melanoma in Swiss Patients: A clinicopathological comparisonKaufmann, C., Mangana, J., Cheng, P., Ramelyte, E., Goldinger, S. M., Levesque, M. P. and Dummer, R. (2017). Thin melanoma in Swiss Patients: A clinicopathological comparison. HOBOKEN: WILEY. |
|
2017 Conference Publication The peripheral blood TCR repertoire might facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanomaSchindler, S., Courtier, A., Jaberg-Bentele, N., Goldinger, S., Manuel, M., Perez, S., Mouret, J. -F., Nguyen-Kim, T. D. L., Raaijmakers, M., Kvistborg, P., Pasqua, N., Haanen, J., Dummer, R. and Levesque, M. (2017). The peripheral blood TCR repertoire might facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma. HOBOKEN: WILEY. |
|
2017 Journal Article Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?Haueis, Silvia A., Kranzlin, Pascale, Mangana, Joanna, Cheng, Phil F., Urosevic-Maiwald, Mirjana, Braun, Ralph P., Levesque, Mitchell P., Dummer, Reinhard and Goldinger, Simone M. (2017). Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?. Melanoma Research, 27 (3), 231-237. doi: 10.1097/CMR.0000000000000338 |
|
2017 Conference Publication Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1)da Silva, Ines Esteves Domingues Pires, Johnpulle, Romany Anne Nilanthi, Banks, Patricia Diana, Grass, G. Daniel, Smith, Jess Louise, Everett, Ashlyn S., Goldinger, Simone M., -Thomson, Rachel Roberts, Millward, Michael, Glitza, Isabella Claudia, Haydu, Lauren Elaine, Atkinson, Victoria, Wang, Tim, Eroglu, Zeynep, Conry, Robert Martin, Shackleton, Mark J., Hong, Angela, Long, Georgina V., Johnson, Douglas Buckner and Menzies, Alexander M. (2017). Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1). 53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 02-07, 2017. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/JCO.2017.35.15_suppl.9513 |
|
2017 Conference Publication Hyperproliferative keratinocytic cutaneous adverse events and inflammatory palmoplantar erythrodysesthesia in melanoma patients treated with encorafenib compared to other BRAF inhibitorsGoldinger, Simone M., Graf, Natalie P., Galliker, Nadja, Conrad, Samuel and Dummer, Reinhard (2017). Hyperproliferative keratinocytic cutaneous adverse events and inflammatory palmoplantar erythrodysesthesia in melanoma patients treated with encorafenib compared to other BRAF inhibitors. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 02-06, 2017. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/JCO.2017.35.15_suppl.9590 |
|
2017 Conference Publication Re-challenge with BRAF-directed treatment: A multi-institutional retrospective studyValpione, Sara, Carlino, Matteo S., Mangana, Joanna, Mooradian, Meghan, McArthur, Grant A., Schadendorf, Dirk, Hauschild, Axel, Long, Georgina V., Arance, Ana M., Ascierto, Paolo Antonio, Maio, Michele, De Rosa, Francesco, Larkin, James M. G., Park, John J., Goldinger, Simone M., Flaherty, Keith, Xu, Wen, Livingstone, Elisabeth, Weichenthal, Michael and Lorigan, Paul (2017). Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study. 53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 02-07, 2017. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/JCO.2017.35.15_suppl.9512 |
|
2017 Journal Article Adjuvant Therapy in High-Risk Stage III Cutaneous MelanomaKaufmann, Fabrice and Goldinger, Simone M. (2017). Adjuvant Therapy in High-Risk Stage III Cutaneous Melanoma. International Journal of Radiation Oncology Biology Physics, 98 (1), 15-16. doi: 10.1016/j.ijrobp.2017.01.245 |
|
2017 Journal Article Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLCTumeh, Paul C., Hellmann, Matthew D., Hamid, Omid, Tsai, Katy K., Loo, Kimberly L., Gubens, Matthew A., Rosenblum, Michael, Harview, Christina L., Taube, Janis M., Handley, Nathan, Khurana, Neharika, Nosrati, Adi, Krummel, Matthew F., Tucker, Andrew, Sosa, Eduardo V., Sanchez, Phillip J., Banayan, Nooriel, Osorio, Juan C., Nguyen-Kim, Dan L., Chang, Jeremy, Shintaku, I. Peter, Boasberg, Peter D., Taylor, Emma J., Munster, Pamela N., Algazi, Alain P., Chmielowski, Bartosz, Dummer, Reinhard, Grogan, Tristan R., Elashoff, David ... Daud, Adil (2017). Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunology Research, 5 (5), 417-424. doi: 10.1158/2326-6066.CIR-16-0325 |
|
2017 Journal Article Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapyNosrati, Adi, Tsai, Katy K., Goldinger, Simone M., Tumeh, Paul, Grimes, Barbara, Loo, Kimberly, Algazi, Alain P., Thi Dan Linh Nguyen-Kim, , Levesque, Mitchell, Dummer, Reinhard, Hamid, Omid and Daud, Adil (2017). Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. British Journal of Cancer, 116 (9), 1141-1147. doi: 10.1038/bjc.2017.70 |
|
2017 Journal Article Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanomaZimmer, Lisa, Apuri, Susmitha, Eroglu, Zeynep, Kottschade, Lisa A., Forschner, Andrea, Gutzmer, Ralf, Schlaak, Max, Heinzerling, Lucie, Krackhardt, Angela M., Loquai, Carmen, Markovic, Svetomir N., Joseph, Richard W., Markey, Kelly, Utikal, Jochen S., Weishaupt, Carsten, Goldinger, Simone M., Sondak, Vernon K., Zager, Jonathan S., Schadendorf, Dirk and Khushalani, Nikhil I. (2017). Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. European Journal of Cancer, 75, 47-55. doi: 10.1016/j.ejca.2017.01.009 |
|
2017 Journal Article A review of serious adverse effects under treatment with checkpoint inhibitorsHeinzerling, Lucie and Goldinger, Simone M. (2017). A review of serious adverse effects under treatment with checkpoint inhibitors. Current Opinion in Oncology, 29 (2), 136-144. doi: 10.1097/CCO.0000000000000358 |
|
2017 Journal Article Developments in targeted therapy in melanomaAmann, V. C., Ramelyte, E., Thurneysen, S., Pitocco, R., Bentele-Jaberg, N., Goldinger, S. M., Dummer, R. and Mangana, J. (2017). Developments in targeted therapy in melanoma. Ejso, 43 (3), 581-593. doi: 10.1016/j.ejso.2016.10.014 |
|
2017 Journal Article Critical aspects to achieve a high-quality melanoma clinicDummer, Reinhard, Ramelyte, Egle, Levesque, Mitch, Goldinger, Simone M. and Braun, Ralph P. (2017). Critical aspects to achieve a high-quality melanoma clinic. Current Opinion in Oncology, 29 (2), 145-150. doi: 10.1097/CCO.0000000000000357 |
|
2016 Journal Article Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?Diem, Stefan, Keller, Fabienne, Ruesch, Reinhard, Maillard, Samia A., Speiser, Daniel E., Dummer, Reinhard, Siano, Marco, Urner-Bloch, Ursula, Goldinger, Simone M. and Flatz, Lukas (2016). Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?. Journal of Immunotherapy, 39 (9), 379-382. doi: 10.1097/CJI.0000000000000143 |
|
2016 Journal Article An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxelThurneysen, S., Cheng, P. F., Nagel, H. W., Kunz, M., Jaberg-Bentele, N., Nageli, M., Ziegler, M., Guenova, E., Goldinger, S. M., Mangana, J., Levesque, M. P. and Dummer, R. (2016). An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel. British Journal of Dermatology, 175 (5), 966-978. doi: 10.1111/bjd.14727 |
|
2016 Conference Publication A phase I, open-label study of pasireotide in patients with BRAF-and NRAS-wild type, unresectable and or metastatic melanomaDummer, R., Michielin, O. A., Nageli, M., Goldinger, S. M., Campigotto, F., Kriemler-Krahn, U., Schmid, H., Pedroncelli, A., Micaletto, S. and Schadendorf, D. (2016). A phase I, open-label study of pasireotide in patients with BRAF-and NRAS-wild type, unresectable and or metastatic melanoma. OXFORD: OXFORD UNIV PRESS. doi: 10.1093/annonc/mdw379.43 |
|
2016 Conference Publication Systemic treatment influences on immune accessibility of melanoma: A retrospective histopathological investigationKrahenbuhl, L., Goldinger, S. M., Kerl, K., Kempf, W., Chevolet, I., Brochez, L., Cheng, P., Mangana, J., Levesque, M. P. and Dummer, R. (2016). Systemic treatment influences on immune accessibility of melanoma: A retrospective histopathological investigation. OXFORD: OXFORD UNIV PRESS. doi: 10.1093/annonc/mdw379.28 |
|
2016 Conference Publication Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect the phenotype switch?Haueis, S., Kranzlin, P., Cheng, P., Mangana, J., Dummer, R. and Goldinger, S. (2016). Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect the phenotype switch?. HOBOKEN: WILEY-BLACKWELL. |
